Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutamic acid decarboxylase 65 (GAD65) is an enzyme that catalyzes the decarboxylation of glutamate to gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the central nervous system. GAD65 is one of two major isoforms of glutamate decarboxylase and is a key autoantigen in type 1 diabetes and several neurological autoimmune disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamic Acid Decarboxylase 65 (GAD65).